Clinical Trial Update: Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating afuresertib plus fulvestrant in locally advanced or metastatic HR+/HER2- breast cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afuresertib (afuresertib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Laekna Limited | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING